Compare ING Groep NV (ING) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Neurocrine Biosciences Inc — how do they compare? ING Groep NV trades at $32.9 (market cap $92.65B), while Neurocrine Biosciences Inc trades at $175.74 (market cap $17.40B). The key difference: ING Groep NV is far larger — about 5.3× Neurocrine Biosciences Inc's market cap, and ING Groep NV pays a 3.93% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| ING | NBIX | |
|---|---|---|
Market Cap | $92.65B | $17.40B |
Sector | Financials | Health |
52-Week High | $33.31 | $180.55 |
52-Week Low | $22.71 | $123.10 |
Dividend Yield | 3.93% | — |
Enterprise Value | — | $16.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $32.13, down 0.62% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 EPS of $0.63, beating expectations of $0.60, continuing a trend of earnings beats. Revenue for 2025 reached $22.90 billion with a net income margin of 27.84%. Recent strategic moves include a stake acquisition in Spain's Singular Bank and the rollout of a global subscription banking model to diversify revenue streams.
The outlook for ING is positive, supported by strong analyst consensus with 62.5% buy ratings and intrinsic value estimates around $34 from DCF analysis. Opportunities include European banking sector strength and net interest income upside from potential ECB rate hikes. Key risks involve persistent negative operating cash flow trends and competitive pressures in digital banking. The stock appears fairly valued with a P/E of 12.96 and P/B of 1.6.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% with strong bullish momentum. Recent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, underscore robust growth. The stock shows bullish technical signals with support at $170 and resistance at $173. Revenue growth accelerated to $2.86 billion in 2025, with net income margin improving to 21.55% in 2026 projections. Positive news highlights pipeline advancements and the Soleno acquisition.
Outlook remains positive with a consensus price target of $196.08, implying 13% upside. Key opportunities include sustained earnings growth and pipeline expansion, while risks involve clinical trial outcomes and competitive pressures. Institutional sentiment is strongly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
